New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
As immune-related pathways involved in the pathogenesis of psoriasis are elucidated, new biologic treatments targeting these steps of the psoriatic immune cascade are developed. In this article, we review the literature on IL-23 and IL-17 inhibitors in the pipeline for use in moderate to severe psoriasis. Numerous pipeline biologic therapies, including risankizumab, guselkumab, tildrakizumab, ixekizumab, and brodalumab, are being investigated in phase 2 and 3 studies to establish the efficacy and safety of these new agents. Of these newest biologics being studied for psoriasis, ixekizumab has been approved and brodalumab is pending approval by the US Food and Drug Administration.
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Joanna
J
Dong
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gary
G
Goldenberg
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D001688:Biological Products / Q000008:administration & dosage / Q000494:pharmacology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000494:pharmacology; D017277:Drug Approval; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology; D053759:Interleukin-23 / Q000037:antagonists & inhibitors* / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D001688:Biological Products; D003879:Dermatologic Agents; D020381:Interleukin-17; D053759:Interleukin-23